Home › Compare › JASUF vs ABBV
JASUF yields 8000.00% · ABBV yields 3.06%● Live data
📍 JASUF pulled ahead of the other in Year 1
Combined, JASUF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JASUF + ABBV for your $10,000?
Jasmine International Public Company Limited provides telecommunications services to individual and corporate clients in Thailand. The company provides high-speed connectivity; Internet services and applications; and software development, distribution, and general software services, including software system that supports value added services for broadband Internet business. It also offers marine and submarine optical fiber maintenance services; international private leased-circuit, Internet protocol virtual private network services, leased line Internet services, managed network services through optic fiber and copper cable networks, National Internet Exchange services, and co-location services and satellite communications. In addition, the company provides data center services; online movie and internet protocol television services; fixed-line services; international calling cards services; wireless communication services through very small aperture terminal; satellite phone services, and small mobile handset and fixed handset for users to use the service from a fixed indoor location in a remote area; and distributes equipment. Further, it engages in system integration, equipment sourcing, system design, and IT systems implementation for government and private sectors; cloud computing; the consultancy, design, and implementation of computer and IT network systems; the provision of space rental services; and investing in telecommunications infrastructure business, other assets, securities, and/or instruments. The company was founded in 1982 and is headquartered in Nonthaburi, Thailand.
Full JASUF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.